-- 歐盟委員會週四表示,已對羅馬尼亞切爾納沃德核電廠1號機組價值32億歐元(約37.7億美元)的核能援助計畫展開調查,理由是擔心該計畫可能存在違反國家援助規定的問題。 羅馬尼亞於2026年1月向歐盟委員會通報了一項計劃,旨在翻新並延長該反應器的使用壽命,同時保持其706兆瓦的裝機容量,使其能夠再運行30年。 歐盟委員會表示,該反應器自1996年投入運作以來,供應了羅馬尼亞約10%的電力,其升級改造對於確保長期低碳電力供應至關重要。 該計畫還旨在加強能源安全,並支持歐盟的脫碳目標,羅馬尼亞國家核電公司(Nuclearelectrica National Company)將作為營運商和受益方。 歐盟委員會表示,該翻新項目的總投資金額估計為32億歐元,這反映了延長該核電廠運作壽命所需的投資規模。 羅馬尼亞計劃透過一系列支持措施為該項目提供資金,其中包括6億歐元的贈款和國家擔保的與投資相關的貸款。 其他支援措施包括一項為期30年的雙向差價合約,以穩定收入,以及在建設和營運期間抵禦監管變化的保護措施。 歐盟委員會表示,其初步審查認為該項目是必要的,並且有利於經濟活動,但對援助是否完全符合歐盟規則表示懷疑。 歐盟委員會質疑援助方案規模是否過大,因為這些支持措施的組合可能會過度降低營運商的財務風險。 歐盟委員會表示,它還在審查該計劃是否繼續鼓勵高效運營,同時確保國家不會承擔過多的專案風險。 歐盟委員會補充說,進一步的審查將檢視對市場競爭的潛在影響,包括差價合約的設計是否會削弱營運或維護誘因。 委員會表示,他們也對現有保障措施是否足以防止援助款項間接惠及消費者或特定市場參與者表示擔憂。 調查現已允許羅馬尼亞和第三方提交回饋意見,委員會強調,此次審查並未預判最終結果。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.